Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 13/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 2/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987114 | 0.75 | ADORA2A (0.62) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL21170805 | 0.68 | PI4KA (0.51) | ADORA2AADORA1HSP90AB1ERBB2PI4KA | |
| SCHEMBL21877976 | 0.67 | FBP1 (0.54) | ADORA2AADORA1ADORA2BADORA3HSP90AB1 | |
| SCHEMBL982883 | 0.66 | HSPA5 (0.40) | ADORA2AADORA1ADORA2BADORA3HSP90AB1 | |
| SCHEMBL5039630 | 0.65 | ADORA2A (0.38) | ADORA2AADORA1ADORA2BADORA3HSP90AB1 | |
| SCHEMBL14175361 | 0.64 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL5083011 | 0.64 | PI4KA (0.55) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL1096911 | 0.63 | AMD1 (0.49) | — | |
| SCHEMBL1755068 | 0.62 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL15689328 | 0.62 | ADORA2A (0.65) | ADORA2AADORA1ADORA2BADORA3FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962863-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | Conforma Therapeutics Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | ADORA2A 116/4885ADORA1 198/4885ADORA2B 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.